# Novo Nordisk

id: ent_novo-nordisk  
wikidata: Q818846  
kind: organization  
timeline: /timelines/novo-nordisk.md  
page: /record/novo-nordisk  
same_as: https://asof.is/record/novo-nordisk (how to cite the id: /identifiers.md)  

Novo Nordisk is a Danish pharmaceutical company, headquartered in Bagsvaerd Denmark. Its CEO is Maziar Mike Doustdar, since 2025. It reported revenue of 309.06B DKK for the period ended December 31, 2025.

## Key facts

- CEO: Maziar Mike Doustdar (since 2025) · claim: /claim/clm_09DBC29C37EF.md
- Chair: Lars Rebien Sørensen · claim: /claim/clm_572A7A46A90E.md
- Headquarters: Bagsvaerd Denmark · claim: /claim/clm_71389B010ACD.md
- Revenue: 309.06B DKK (to 2025-12-31) [recorded: 309,064,000,000 DKK] · claim: /claim/clm_8F7EC31D7FFC.md
- Employees: 69,505 employee (as of 2025-12-31) · claim: /claim/clm_8EB909BEF688.md
- Ticker: NVO · NYSE · claim: /claim/clm_A89E46223B59.md

## Questions

**Who is the CEO of Novo Nordisk?** Maziar Mike Doustdar, since 2025, as the AsOf record states with its sources.

**Where is Novo Nordisk headquartered?** Bagsvaerd Denmark.

**What is Novo Nordisk's revenue?** 309.06B DKK for the period ended December 31, 2025.

## Fact pages

One page per fact: the current value with its sources, then every dated value and what replaced what. Fetch any of them as markdown.

- [Novo Nordisk CEO](/record/novo-nordisk/ceo.md)
- [Novo Nordisk chair](/record/novo-nordisk/chair.md)
- [Novo Nordisk headquarters](/record/novo-nordisk/headquarters.md)
- [Novo Nordisk employees](/record/novo-nordisk/employees.md)
- [Novo Nordisk revenue](/record/novo-nordisk/revenue.md)
- [Novo Nordisk net income](/record/novo-nordisk/net_income.md)
- [Novo Nordisk operating income](/record/novo-nordisk/operating_income.md)

## Current state

What the record asserts: claims that held, valid by their sources or primary-sourced at confidence 0.7 or more. Unverified, disputed, retracted and review-marked claims are listed below, labelled, not here.

- [Novo Nordisk](/record/novo-nordisk.md) | registrant_name | NOVO NORDISK A S | valid undated to present | conf 0.95 | valid | [clm_5C5C98A60302](/claim/clm_5C5C98A60302.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | ceo | Maziar Mike Doustdar | valid 2025-08-07 to present | conf 0.95 | valid | [clm_09DBC29C37EF](/claim/clm_09DBC29C37EF.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm
- [Novo Nordisk](/record/novo-nordisk.md) | chair | Lars Rebien Sørensen | valid undated to present | conf 0.95 | valid | [clm_572A7A46A90E](/claim/clm_572A7A46A90E.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm
- [Novo Nordisk](/record/novo-nordisk.md) | headquarters | Bagsvaerd Denmark | valid undated to present | conf 0.95 | valid | [clm_71389B010ACD](/claim/clm_71389B010ACD.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | revenue | 309,064,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_8F7EC31D7FFC](/claim/clm_8F7EC31D7FFC.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | net_income | 102,434,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_F536BDE429B7](/claim/clm_F536BDE429B7.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | operating_income | 127,658,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_672756B8F8A9](/claim/clm_672756B8F8A9.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_assets | 542,902,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_BCB17EC648AA](/claim/clm_BCB17EC648AA.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | employees | 69,505 employee | valid 2025-12-31 to present | conf 0.95 | valid | [clm_8EB909BEF688](/claim/clm_8EB909BEF688.md)
  sources: https://www.wikidata.org/wiki/Q818846, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm, https://ml-eu.globenewswire.com/Resource/Download/7c7c1d6f-42c0-4e8f-821c-93ff9a0858c0
- [Novo Nordisk](/record/novo-nordisk.md) | listed_on | OTC | valid undated to present | conf 0.95 | valid | [clm_07286C13C782](/claim/clm_07286C13C782.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | listed_on | NYSE | valid undated to present | conf 0.95 | valid | [clm_AECDFCB7C547](/claim/clm_AECDFCB7C547.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 194,047,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_51EBABE50856](/claim/clm_51EBABE50856.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm

## All claims

One claim per line, newest first. Superseded claims stay visible.

- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 194,047,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_51EBABE50856](/claim/clm_51EBABE50856.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | operating_income | 127,658,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_672756B8F8A9](/claim/clm_672756B8F8A9.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | employees | 69,505 employee | valid 2025-12-31 to present | conf 0.95 | valid | [clm_8EB909BEF688](/claim/clm_8EB909BEF688.md)
  sources: https://www.wikidata.org/wiki/Q818846, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm, https://ml-eu.globenewswire.com/Resource/Download/7c7c1d6f-42c0-4e8f-821c-93ff9a0858c0
- [Novo Nordisk](/record/novo-nordisk.md) | revenue | 309,064,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_8F7EC31D7FFC](/claim/clm_8F7EC31D7FFC.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_assets | 542,902,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_BCB17EC648AA](/claim/clm_BCB17EC648AA.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | net_income | 102,434,000,000 DKK | valid 2025-12-31 to present | conf 0.95 | valid | [clm_F536BDE429B7](/claim/clm_F536BDE429B7.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | ceo | Maziar Mike Doustdar | valid 2025-08-07 to present | conf 0.95 | valid | [clm_09DBC29C37EF](/claim/clm_09DBC29C37EF.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm
- [Novo Nordisk](/record/novo-nordisk.md) | operating_income | 128,339,000,000 DKK | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_672756B8F8A9](/claim/clm_672756B8F8A9.md) | [clm_109041F6F3C0](/claim/clm_109041F6F3C0.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_assets | 465,795,000,000 DKK | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_BCB17EC648AA](/claim/clm_BCB17EC648AA.md) | [clm_36763BC50C4E](/claim/clm_36763BC50C4E.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 143,486,000,000 DKK | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_51EBABE50856](/claim/clm_51EBABE50856.md) | [clm_4145313CD790](/claim/clm_4145313CD790.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | employees | 77,349 employee | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_8EB909BEF688](/claim/clm_8EB909BEF688.md) | [clm_6A7CC2B7840B](/claim/clm_6A7CC2B7840B.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | net_income | 100,988,000,000 DKK | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_F536BDE429B7](/claim/clm_F536BDE429B7.md) | [clm_8A5C5EE097FD](/claim/clm_8A5C5EE097FD.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | revenue | 290,403,000,000 DKK | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_8F7EC31D7FFC](/claim/clm_8F7EC31D7FFC.md) | [clm_A3B9347CE850](/claim/clm_A3B9347CE850.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | employees | 64,319 employee | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_6A7CC2B7840B](/claim/clm_6A7CC2B7840B.md) | [clm_5B1E4C20C74E](/claim/clm_5B1E4C20C74E.md)
  sources: https://www.wikidata.org/wiki/Q818846, https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf
- [Novo Nordisk](/record/novo-nordisk.md) | operating_income | 102,574,000,000 DKK | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_109041F6F3C0](/claim/clm_109041F6F3C0.md) | [clm_792EA3966BEF](/claim/clm_792EA3966BEF.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | revenue | 232,261,000,000 DKK | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_A3B9347CE850](/claim/clm_A3B9347CE850.md) | [clm_8ED842A2DCE7](/claim/clm_8ED842A2DCE7.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_assets | 314,486,000,000 DKK | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_36763BC50C4E](/claim/clm_36763BC50C4E.md) | [clm_A36685A1C540](/claim/clm_A36685A1C540.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 106,561,000,000 DKK | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_4145313CD790](/claim/clm_4145313CD790.md) | [clm_A40D8D2F280A](/claim/clm_A40D8D2F280A.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | net_income | 83,683,000,000 DKK | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_8A5C5EE097FD](/claim/clm_8A5C5EE097FD.md) | [clm_A49F4F076521](/claim/clm_A49F4F076521.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | net_income | 55,525,000,000 DKK | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_A49F4F076521](/claim/clm_A49F4F076521.md) | [clm_1A208DF6F487](/claim/clm_1A208DF6F487.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | revenue | 176,954,000,000 DKK | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_8ED842A2DCE7](/claim/clm_8ED842A2DCE7.md) | [clm_459BEEC0AB43](/claim/clm_459BEEC0AB43.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_assets | 241,257,000,000 DKK | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_A36685A1C540](/claim/clm_A36685A1C540.md) | [clm_56708B41C767](/claim/clm_56708B41C767.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 83,486,000,000 DKK | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_A40D8D2F280A](/claim/clm_A40D8D2F280A.md) | [clm_800F88E2D840](/claim/clm_800F88E2D840.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | employees | 55,185 employee | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_5B1E4C20C74E](/claim/clm_5B1E4C20C74E.md) | [clm_D62CD294DD73](/claim/clm_D62CD294DD73.md)
  sources: https://www.wikidata.org/wiki/Q818846, https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2023/novo-nordisk-annual-report-2022.pdf
- [Novo Nordisk](/record/novo-nordisk.md) | operating_income | 74,809,000,000 DKK | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_792EA3966BEF](/claim/clm_792EA3966BEF.md) | [clm_F3418E0D3161](/claim/clm_F3418E0D3161.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 70,746,000,000 DKK | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_800F88E2D840](/claim/clm_800F88E2D840.md) | [clm_1B204B243A08](/claim/clm_1B204B243A08.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | operating_income | 58,644,000,000 DKK | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_F3418E0D3161](/claim/clm_F3418E0D3161.md) | [clm_4E462623C749](/claim/clm_4E462623C749.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_assets | 194,508,000,000 DKK | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_56708B41C767](/claim/clm_56708B41C767.md) | [clm_6D30A77C658F](/claim/clm_6D30A77C658F.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | employees | 48,478 employee | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_D62CD294DD73](/claim/clm_D62CD294DD73.md) | [clm_71916DF751CE](/claim/clm_71916DF751CE.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | net_income | 47,757,000,000 DKK | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_1A208DF6F487](/claim/clm_1A208DF6F487.md) | [clm_8F5ADB2C07ED](/claim/clm_8F5ADB2C07ED.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | revenue | 140,800,000,000 DKK | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_459BEEC0AB43](/claim/clm_459BEEC0AB43.md) | [clm_DEF63B463032](/claim/clm_DEF63B463032.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_assets | 144,922,000,000 DKK | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_6D30A77C658F](/claim/clm_6D30A77C658F.md) | [clm_072CD0878EE5](/claim/clm_072CD0878EE5.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | net_income | 42,138,000,000 DKK | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_8F5ADB2C07ED](/claim/clm_8F5ADB2C07ED.md) | [clm_2112055E65B9](/claim/clm_2112055E65B9.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | employees | 45,323 employee | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_71916DF751CE](/claim/clm_71916DF751CE.md) | [clm_5D92621F8B64](/claim/clm_5D92621F8B64.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | revenue | 126,946,000,000 DKK | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_DEF63B463032](/claim/clm_DEF63B463032.md) | [clm_67D64D48F06E](/claim/clm_67D64D48F06E.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | operating_income | 54,126,000,000 DKK | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_4E462623C749](/claim/clm_4E462623C749.md) | [clm_D272A9AE2D76](/claim/clm_D272A9AE2D76.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 63,325,000,000 DKK | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_1B204B243A08](/claim/clm_1B204B243A08.md) | [clm_D44DDD0D515C](/claim/clm_D44DDD0D515C.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | employees | 43,258 employee | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_5D92621F8B64](/claim/clm_5D92621F8B64.md) | [clm_277344156E80](/claim/clm_277344156E80.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 57,593,000,000 DKK | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_D44DDD0D515C](/claim/clm_D44DDD0D515C.md) | [clm_43C7BF9EE087](/claim/clm_43C7BF9EE087.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | operating_income | 52,483,000,000 DKK | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_D272A9AE2D76](/claim/clm_D272A9AE2D76.md) | [clm_B2B75C38DC99](/claim/clm_B2B75C38DC99.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | net_income | 38,951,000,000 DKK | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_2112055E65B9](/claim/clm_2112055E65B9.md) | [clm_DA4855A5F51A](/claim/clm_DA4855A5F51A.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | revenue | 122,021,000,000 DKK | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_67D64D48F06E](/claim/clm_67D64D48F06E.md) | [clm_F0275DE8A21D](/claim/clm_F0275DE8A21D.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | total_equity | 51,839,000,000 DKK | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_43C7BF9EE087](/claim/clm_43C7BF9EE087.md) | [clm_3322844F3158](/claim/clm_3322844F3158.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm
- [Novo Nordisk](/record/novo-nordisk.md) | x_username | novonordisk | valid 2010-09-23 to present | conf 0.60 | unverified | [clm_C639BE305784](/claim/clm_C639BE305784.md)
  sources: https://www.wikidata.org/wiki/Q818846
- [Novo Nordisk](/record/novo-nordisk.md) | website | https://www.novonordisk.com | valid undated to present | conf 0.45 | unverified | [clm_F171E5861BC9](/claim/clm_F171E5861BC9.md)
  sources: https://www.wikidata.org/wiki/Q818846
- [Novo Nordisk](/record/novo-nordisk.md) | listed_on | OTC | valid undated to present | conf 0.95 | valid | [clm_07286C13C782](/claim/clm_07286C13C782.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | ticker | NONOF | valid undated to present | conf 0.95 | valid | [clm_2B51766EA897](/claim/clm_2B51766EA897.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | sic_industry | Pharmaceutical Preparations (2834) | valid undated to present | conf 0.95 | valid | [clm_52574002BF9D](/claim/clm_52574002BF9D.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | cik | 0000353278 | valid undated to present | conf 0.95 | valid | [clm_52A9D25B5082](/claim/clm_52A9D25B5082.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | chair | Lars Rebien Sørensen | valid undated to present | conf 0.95 | valid | [clm_572A7A46A90E](/claim/clm_572A7A46A90E.md)
  sources: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm
- [Novo Nordisk](/record/novo-nordisk.md) | registrant_name | NOVO NORDISK A S | valid undated to present | conf 0.95 | valid | [clm_5C5C98A60302](/claim/clm_5C5C98A60302.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | headquarters | Bagsvaerd Denmark | valid undated to present | conf 0.95 | valid | [clm_71389B010ACD](/claim/clm_71389B010ACD.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | fiscal_year_end | 12-31 | valid undated to present | conf 0.95 | valid | [clm_A875D9470529](/claim/clm_A875D9470529.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | ticker | NVO | valid undated to present | conf 0.95 | valid | [clm_A89E46223B59](/claim/clm_A89E46223B59.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278
- [Novo Nordisk](/record/novo-nordisk.md) | listed_on | NYSE | valid undated to present | conf 0.95 | valid | [clm_AECDFCB7C547](/claim/clm_AECDFCB7C547.md)
  sources: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.